Aminothiadiazole (NSC #4728) in patients with advanced colon cancer. A phase II study of the Eastern Cooperative Oncology Group.
The Eastern Cooperative Oncology Group (ECOG) studied 29 patients with advanced measurable colon cancer who were treated with Aminothiadiazole (NSC #4728) 125 mg/m2 intravenously. Allopurinol 300 mg daily was taken by all patients during treatment. Three patients (12%) demonstrated partial responses on this regimen. Hematologic toxicity did not occur. Gastrointestinal toxicity was severe in 16% of patients and consisted primarily of vomiting and diarrhea. No life-threatening toxicity was encountered. A lack of appreciable toxicity together with the few responses seen suggest that further studies at higher dose may be indicated.
Asbury
R F
RF
University of Rochester Cancer Center, New York.
Kramar
A
A
Haller
D G
DG
D000493:Allopurinol / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D009362:Neoplasm Metastasis; D013830:Thiadiazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D013830:Thiadiazoles; D000493:Allopurinol; C010852:2-amino-1,3,4-thiadiazole